In this review, we summarize the relevant scientific advances that led to the development of
infectious cell culture systems for hepatitis C virus (HCV) with the corresponding challenges …

The ability to use structure-based design and engineering to control the molecular shape
and reactivity of an immunogen to induce protective responses shows great promise, along …

Hepatitis C virus (HCV) continues to spread worldwide with an annual increase of 1.75
million new infections. The number of HCV cases in the US is now greater than the number …

Conformational dynamics of viral envelope proteins seem to be involved in mediating
evasion from neutralizing antibodies (NAbs) by mechanisms that limit exposure of …

Abstract Background and Aims Lack of tractable immunocompetent animal models
amenable to robust experimental challenge impedes vaccine efforts for HCV. Infection with …

Conclusions: We show how N‐linked glycosylation motifs can trigger dramatic changes in
HCV sensitivity to nAb, independent of glycan occupancy. These findings aid in the …

Hepatitis C virus (HCV) belongs to the Hepacivirus genus and is genetically heterogeneous,
with seven major genotypes further divided into several recognized subtypes. HCV origin …

The lack of robust immunocompetent animal models for hepatitis C virus (HCV) impedes
vaccine development and studies of immune responses. Norway rat hepacivirus (NrHV) …

Abstract E1 and E2 (E1E2), the fusion proteins of Hepatitis C Virus (HCV), are unlike that of
any other virus yet described, and the detailed molecular mechanisms of HCV entry/fusion …

Hepatitis C virus (HCV) is a major causative agent of acute and chronic hepatitis. It is
estimated that 400,000 people die every year from chronic HCV infection, mostly from …